Contra: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”

Stavros Apostolakis; Eduard Shantsila; Gregory Y. H. Lip; Deirdre A. Lane

doi:10.1160/TH09-08-0563

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 102(05): 914-915
DOI: 10.1160/TH09-08-0563

Pro/Contra Article

Schattauer GmbH

Contra: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”

Stavros Apostolakis

¹Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

,

Eduard Shantsila

¹Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

,

Gregory Y. H. Lip

¹Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

,

Deirdre A. Lane

¹Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

› Author Affiliations

Abstract

Full Text

References

References
1 Hughes M, Lip GY. Guideline Development Group National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care National Institute for Health and Clinical Excellence Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
2 Poli D, Antonucci E, Grifoni E. et al. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost 2009; 101: 938-942.
3 Fuster V, Rydén LE, Cannom DS. et al. American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association;Heart Rhythm Society ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 08: 651-745.
4 Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost 2009; 102: 268-278.
5 McBane RD, Hodge DO, Wysokinski WE. Clinical and echocardiographic measures governing throm-boembolism destination in atrial fibrillation. Thromb Haemost 2008; 99: 951-955.
6 Singer DE, Chang Y, Fang MC. et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
7 Lip GY. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. Thromb Haemost 2008; 100: 11-13.
8 The ACTIVE Writing Group on behalf of the ACTIVE Investigators: Clopidogrel plus aspirin versus oral anticoagulation for atrial fi brillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 367. 1903-1912.
9 The ACTIVE Investigators: Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009 360. 2066-2067.
10 Man-Son-Hing M, O’Connor AM, Drake E. et al. The effect of qualitative vs. quantitative presentation of probability estimates on patient decision-making: a randomized trial. Health Expect 2002; 05: 246-255.
11 Nieuwlaat R, Capucci A, Camm AJ. et al. Euro Heart Survey Investigators: Atrial fibrillation management: A prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-2434.
12 Jeffrey S. ACTIVE-A: Clopidogrel and aspirin reduce CV events in atrial fibrillation. theheart.org. [Clinical Conditions > Arrhythmia/EP > Arrhythmia/ EP]; Mar 31, 2009. Accessed at http://www.theheart. org/article/955787 do on Aug 12. 2009
13 Mant JW. Pro: ‘Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation’. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation. Thromb Haemost 2008; 100: 14-15.
14 Hylek EM. Contra: ‘Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation’. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Thromb Haemost 2008; 100: 16-17.
15 Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S. ACTIVE W Investigators: Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centres and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
16 Tay KH, Lip GY, Lane DA. Atrial fibrillation and stroke risk prevention in real-life clinical practice. Thromb Haemost 2009; 101: 415-416.
17 Connolly SJ, Ezekowitz MD, Yusuf S. et al. The RELY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009 epub ahead of print..
18 Lip GYH, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2009 epub ahead of print..